Seroprevalence of SARS-CoV-2 among Internal Medicine Residents at a Major Academic Medicine Residency Program.
Adult
Antibodies, Viral
/ blood
Biomarkers
/ blood
COVID-19
/ blood
COVID-19 Testing
Female
Humans
Infectious Disease Transmission, Patient-to-Professional
Internal Medicine
/ education
Internship and Residency
Male
Occupational Exposure
Prevalence
Rhode Island
/ epidemiology
Risk Factors
SARS-CoV-2
/ immunology
Seroepidemiologic Studies
SARS-CoV-2
internal medicine residents
seroprevalence
Journal
Rhode Island medical journal (2013)
ISSN: 2327-2228
Titre abrégé: R I Med J (2013)
Pays: United States
ID NLM: 101605827
Informations de publication
Date de publication:
01 Jun 2021
01 Jun 2021
Historique:
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
8
6
2021
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease (COVID-19) are a significant cause of morbidity and mortality across the United States. Internal medicine (IM) residents are a critical component of the healthcare workforce yet their seroprevalence of SARS-CoV-2 antibodies is largely unknown. The aim of this research was to ascertain the seroprevalences of SARS-CoV-2 among internal medicine residents during the first peak of COVID-19. IM residents were enrolled in a surveillance program that included PCR and antibody testing for SARS-CoV-2 in June 2020. Residents also completed a short questionnaire to obtain sociodemographic information and characterize potential workplace exposure to COVID-19. A total of 101 IM residents participated in the study (out of N=162). Of the 101 samples, three (2.9%) tested positive for SARS-CoV-2 antibodies. No residents tested PCR positive for SARS-CoV-2. The implementation of COVID-19 patient cohorting and the incorporation of telemedicine to communicate with hospitalized patients into clinical practice early in the pandemic may have prevented the spread of the virus among the surveyed clinical trainees. Despite significant engagement with COVID-19 patients, IM residents demonstrated a low rate of SARS-CoV-2 seroprevalence.
Sections du résumé
BACKGROUND
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease (COVID-19) are a significant cause of morbidity and mortality across the United States. Internal medicine (IM) residents are a critical component of the healthcare workforce yet their seroprevalence of SARS-CoV-2 antibodies is largely unknown. The aim of this research was to ascertain the seroprevalences of SARS-CoV-2 among internal medicine residents during the first peak of COVID-19.
METHODS
METHODS
IM residents were enrolled in a surveillance program that included PCR and antibody testing for SARS-CoV-2 in June 2020. Residents also completed a short questionnaire to obtain sociodemographic information and characterize potential workplace exposure to COVID-19.
RESULTS
RESULTS
A total of 101 IM residents participated in the study (out of N=162). Of the 101 samples, three (2.9%) tested positive for SARS-CoV-2 antibodies. No residents tested PCR positive for SARS-CoV-2.
DISCUSSION
CONCLUSIONS
The implementation of COVID-19 patient cohorting and the incorporation of telemedicine to communicate with hospitalized patients into clinical practice early in the pandemic may have prevented the spread of the virus among the surveyed clinical trainees.
CONCLUSION
CONCLUSIONS
Despite significant engagement with COVID-19 patients, IM residents demonstrated a low rate of SARS-CoV-2 seroprevalence.
Substances chimiques
Antibodies, Viral
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20-23Subventions
Organisme : NIMH NIH HHS
ID : R25 MH083620
Pays : United States
Références
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
J Hosp Infect. 2020 Aug;105(4):596-600
pubmed: 32565367
JAMA Intern Med. 2020 Dec 1;180(12):1707-1709
pubmed: 32780100
Am J Epidemiol. 2021 Jan 4;190(1):161-175
pubmed: 32870978